(Q42997999)

12 November 2017

Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes (English)

1 reference

12 November 2017

0 references

7

1 reference

12 November 2017

Marco Antonio Montes-Cano

1

1 reference

12 November 2017

José Raúl García-Lozano

2

1 reference

12 November 2017

Cristina Abad-Molina

3

1 reference

12 November 2017

Manuel Romero-Gómez

4

1 reference

12 November 2017

Natalia Barroso

5

1 reference

12 November 2017

José Aguilar-Reina

6

1 reference

12 November 2017

María Francisca González-Escribano

8

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 July 2010

1 reference

12 November 2017

1 reference

12 November 2017

52

1 reference

12 November 2017

1

1 reference

12 November 2017

33-37

1 reference

Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group

12 November 2017

1 reference

Treatment predictors of a sustained virologic response in hepatitis B and C.

21 January 2018

1 reference

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

21 January 2018

1 reference

Classification of chronic viral hepatitis: a need for reassessment

21 January 2018

1 reference

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin

21 January 2018

1 reference

Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy

21 January 2018

1 reference

Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.

21 January 2018

1 reference

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

Treatment of chronic hepatitis C in Asia: when East meets West.

21 January 2018

1 reference

The Evolution of the Major Hepatitis C Genotypes Correlates with Clinical Response to Interferon Therapy

21 January 2018

1 reference

Adaptation, co-evolution, and human susceptibility to HIV-1 infection.

21 January 2018

1 reference

Adaptation of HIV-1 to human leukocyte antigen class I

21 January 2018

1 reference

Natural history of hepatitis C

21 January 2018

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/HEP.23624

1 reference

12 November 2017

1 reference